Secondary prevention trials after myocardial infarction.
Secondary prevention trials after myocardial infarction have been compared and reviewed. The data suggest that beta-blockers particularly those without intrinsic sympathomimetic activity (ISA) improve long-term survival after myocardial infarction. Platelet-active drugs reduce the rate of reinfarctions and may have a beneficial effect on survival. In contrast lipid-lowering regimens, anticoagulants, calcium channel blockers, and antiarrhythmics have not shown convincing beneficial effects on survival thus far. Difficulties with subgroup analysis and statistical evaluation of treatment effects are discussed.
Furberg
C D
CD
Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103.
D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*